GlassScriptPhysician profile
Vickie M Johnson
NPI 1922338086
$8,128.40
in general payments reported to CMS, 2019-2025
25 companies · $2,200 in 2025
The $2,200 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $948 · 2022: $1,931 · 2023: $1,822 · 2024: $1,227 · 2025: $2,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,971.32 | 2021-2025 | Epclusa |
| Abbvie INC. | $1,490.27 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $544.82 | 2021-2024 | Stelara |
| Janssen Biotech, INC. | $533.14 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.98 | 2021-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $364.69 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $357.24 | 2023-2025 | Cobenfy, Zeposia |
| Novo Nordisk INC | $318.99 | 2022-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $217.76 | 2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.20 | 2023-2025 | Caplyta |
| Redhill Biopharma INC. | $186.39 | 2021 | |
| Qol Medical, LLC | $170.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $159.65 | 2025 | Invega Sustenna |
| Evoke Pharma, INC. | $145.63 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $134.96 | 2021-2023 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $126.77 | 2025 | Ibsrela |
| Tris Pharma INC | $123.57 | 2024 | Quillichew Er, Quillivant, Dyanavel Xr |
| Madrigal Pharmaceuticals | $122.36 | 2025 | Rezdiffra |
| Procept Biorobotics Corporation | $120.35 | 2023 | Aquabeam Robotic System |
| Alexion Pharmaceuticals, INC. | $99.99 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.24 | 2022 | |
| Csl Behring | $90.65 | 2025 | Hizentra |
| Abbott Laboratories | $81.14 | 2025 | Alinity |
| Takeda Pharmaceuticals U.S.A., INC. | $30.17 | 2021-2024 | Entyvio |
| Celgene Corporation | $28.95 | 2021-2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vickie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.